Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants.
Japanese patients with genetic prostate cancer saw survival results on olaparib matching those from major trials.
In Japanese mCRPC patients harboring BRCA pathogenic variants (n=27), real-world olaparib treatment yielded median OS of 18.4 months and 1-year OS rate of 80.6%, consistent with prior trial data. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- cohort_study
- Category
- Other
- Maturity
- Validated
- Journal
- Int J Urol
Why it surfaced
Real-world data confirming olaparib efficacy in BRCA-altered mCRPC in an East Asian cohort; 14% BRCA PV prevalence by CGP has clinical implications for testing protocol design; sample size is small (n=27) warranting conservative interpretation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.